文献速递心血管MR

FIBR-CMR评分:整合纤维蛋白原与心脏磁共振预测STEMI后主要不良事件的新型风险模型

The FIBR-CMR score: a novel risk model integrating fibrinogen and cardiac magnetic resonance for major adverse events after STEMI.
PubMed 文献 · Radiol Med · 2026-10-22

该前瞻性多中心队列纳入532例接受直接PCI的STEMI患者,术后测血浆纤维蛋白原并在7天内行CMR评估左室血栓和室壁瘤。纤维蛋白原≥3.36 g/L独立预测MACCE(HR 1.30),FIBR-CMR评分将患者分为低、中、高风险组,5年MACCE发生率分别为6.0%、15.2%和48.3%, optimism-corrected C-index为0.73。

要点

  • FIBR-CMR评分:纤维蛋白原升高1分、左室血栓2分、室壁瘤2分,总分≥3为高风险。
  • 高风险组5年MACCE发生率48.3%,显著高于中危15.2%和低危6.0%。
  • 纤维蛋白原≥3.36 g/L独立预测MACCE,部分由左室血栓和室壁瘤介导。

关键影像表现/征象

  • CMR用于评估左室血栓和左室室壁瘤。
  • 纤维蛋白原升高独立预测左室血栓(调整OR 1.46,95%CI 1.09-1.96)和左室室壁瘤(调整OR 1.47,95%CI 1.20-1.79)。

诊断标准与关键数值

  • 纤维蛋白原≥3.36 g/L独立预测MACCE(HR 1.30,95%CI 1.10-1.53)。
  • FIBR-CMR评分:纤维蛋白原升高1分,左室血栓2分,左室室壁瘤2分;低危0分、中危1-2分、高危≥3分。
  • 高风险组5年MACCE发生率48.3%,中危15.2%,低危6.0%;optimism-corrected C-index=0.73。

临床应用与阅片要点

  • 对STEMI直接PCI术后患者,可结合纤维蛋白原水平和CMR所示左室血栓/室壁瘤进行风险分层。
  • 评分≥3分提示高危,5年MACCE风险接近一半,应加强随访和管理。

局限性

  • 研究为内部验证(bootstrap重采样),评分需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Survivors of ST-segment elevation myocardial infarction (STEMI) face a substantial residual risk of major adverse cardiovascular and cerebrovascular events (MACCEs). Cardiac magnetic resonance (CMR) excellently delineates structural injury but does not assess the concomitant systemic prothrombotic state. We investigated whether fibrinogen, a key mediator of thrombosis, provides incremental prognostic value beyond CMR for risk stratification.

METHODS: In a prospective multicenter cohort of 532 STEMI patients undergoing primary percutaneous coronary intervention (PCI), plasma fibrinogen was measured post-procedure. CMR was performed within 7 days to assess left ventricular thrombus (LVT) and aneurysm (LVA). The primary endpoint was MACCEs over a median follow-up of 55.5 months. A novel risk score (the Fibrinogen and Cardiac Magnetic Resonance Score, or FIBR-CMR score) was derived from a multivariable Cox model, and its performance was assessed through internal validation using bootstrap resampling (optimism-corrected C-index = 0.73).

RESULTS: Elevated fibrinogen independently predicted LVT (adjusted OR 1.46, 95% CI 1.09-1.96) and LVA (adjusted OR 1.47, 95% CI 1.20-1.79) after adjusting for clinical and CMR confounders. Fibrinogen (≥ 3.36 g/L) independently predicted MACCEs (HR 1.30, 95% CI 1.10-1.53), an effect partially mediated by LVT (48.5%) and LVA (38.0%). The FIBR-CMR score (1 point for elevated fibrinogen, 2 for LVT, 2 for LVA) stratified patients into low (0 points), intermediate (1-2 points), and high (≥ 3 points) risk groups. The high-risk group had a strikingly elevated 5-year MACCE incidence of 48.3%, compared to 15.2% and 6.0% in the intermediate- and low-risk groups, respectively (optimism-corrected C-index = 0.73).

CONCLUSION: The integration of fibrinogen with CMR-defined structural injury provides powerful synergism for risk assessment. The FIBR-CMR score, derived from a prospective multicenter cohort, effectively identifies a high-risk phenotype of STEMI patients. This score now requires external validation but represents a promising step toward personalized risk assessment.

CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov; NCT03768453.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Jiang YJ, Wei L, Hou XC, et al. The FIBR-CMR score: a novel risk model integrating fibrinogen and cardiac magnetic resonance for major adverse events after STEMI. Radiol Med. 2026. PMID: 42911529. doi:10.1007/s11547-026-02285-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。